{"id":"W4410312427","doi":"10.1093/oncolo/oyaf048","title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Astellas Pharma; Oncolytics Biotech; Eisai; Les Laboratories Pierre Fabre; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Roche; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Internal medicine; Trastuzumab; Chemotherapy; Oncology; Hazard ratio; Adverse effect; Quality of life (healthcare); Cohort; Cancer; Breast cancer; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091717,0.0002797726,0.0006376284,0.00009561265,0.00007064209,0.000009767025,0.000211487,0.00009294895,0.00005425773],"category_scores_gemma":[0.000135174,0.0001751991,0.00009268722,0.0004751156,0.0004330839,0.0000780364,0.00004894414,0.0002675322,0.000004133114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005336049,"about_ca_system_score_gemma":0.000252695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001741983,"about_ca_topic_score_gemma":0.0007622375,"domain_scores_codex":[0.9984587,0.00006994264,0.0004536286,0.0003526062,0.0003403998,0.0003246525],"domain_scores_gemma":[0.9982929,0.0004972889,0.0003608096,0.0006161678,0.0001762161,0.00005659853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01256395,0.001745386,0.7567856,0.00004204355,0.0006457125,0.0000140904,0.0007766645,0.0001728214,0.0006030528,0.00005434172,0.00005088854,0.2265455],"study_design_scores_gemma":[0.01932692,0.001196565,0.9742925,0.0002607073,0.0001571186,7.407286e-7,0.000627681,0.00001736781,0.002513531,0.0002957748,0.00114352,0.0001676275],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994795,0.0001397975,0.0001761159,0.001555923,0.0002519596,0.000884835,0.00003292509,0.00007734435,0.002086122],"genre_scores_gemma":[0.9972834,0.00000705525,0.001096425,0.001211075,0.00004648819,0.00009071434,0.00004018477,0.00003321217,0.0001914684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2263779,"threshold_uncertainty_score":0.7144411,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01682158196963432,"score_gpt":0.3043310066982524,"score_spread":0.2875094247286181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}